Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2006The Journal of Infectious DiseasesOpen Access

Efficacy of the Anti‐CandidarAls3p‐N or rAls1p‐N Vaccines against Disseminated and Mucosal Candidiasis

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBrad SpellbergAIAshraf S. IbrahimVAValentina Avanesian

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Spellberg et al. (2006) studied this question.

synapsesocial.com/papers/6a7053c2febe604dd7091e00https://doi.org/10.1086/504691
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)2003 · 194 citations
  2. 2The Anti- <i>Candida albicans</i> Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised Mice2005 · 80 citations
  3. 3Genetic Susceptibility of Mice to Candida albicans Vaginitis Correlates with Host Estrogen Sensitivity2004 · 41 citations
  4. 4Principles and Practice of Infectious Diseases.1991 · 12,069 citations
  5. 5Mice with Disseminated Candidiasis Die of Progressive Sepsis2005 · 238 citations